Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History SPRB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics SPRB

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Spruce Biosciences Inc

SPRB
Current price
0.11 USD +0.012 USD (+12.36%)
Last closed 0.10 USD
ISIN US85209E1091
Sector Healthcare
Industry Biotechnology
Exchange PINK
Capitalization 4 265 361 USD
Yield for 12 month -79.05 %
1Y
3Y
5Y
10Y
15Y
SPRB
21.11.2021 - 28.11.2021

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sleeping patterns. In addition, the company develops SPR202 for the treatment of Congenital Adrenal Hyperplasia (CAH), a chronic and potentially life-threatening rare disease with no cure, and SPR204, a monoclonal antibody antagonist for Post-Bariatric Hypoglycemia. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize various pharmaceutical compounds. It also has a collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize Tildacerfont for the treatment of CAH in Japan. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in South San Francisco, California. Address: 611 Gateway Boulevard, South San Francisco, CA, United States, 94080

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

1.00 USD

P/E Ratio

Dividend Yield

Financials SPRB

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures SPRB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+4 911 000 USD

Last Year

+10 089 000 USD

Current Quarter

+697 000 USD

Last Quarter

+697 000 USD

Current Year

+4 911 000 USD

Last Year

+10 089 000 USD

Current Quarter

+697 000 USD

Last Quarter

EBITDA -57 973 000 USD
Operating Margin TTM -1 994.16 %
Price to Earnings
Return On Assets TTM -60.84 %
PEG Ratio
Return On Equity TTM -135.34 %
Wall Street Target Price 1.00 USD
Revenue TTM 2 909 000 USD
Book Value 0.36 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -75.90 %
Dividend Yield
Gross Profit TTM -44 029 000 USD
Earnings per share -1.33 USD
Diluted Eps TTM -1.33 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation SPRB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 15.32
Price Sales TTM 1.47
Enterprise Value EBITDA -0.23
Price Book MRQ 0.28

Technical Indicators SPRB

For 52 Weeks

0.057 USD 0.61 USD
50 Day MA 0.071 USD
Shares Short Prior Month 136 392
200 Day MA 0.31 USD
Short Ratio 0.31
Shares Short 511 923
Short Percent 1.23 %